Lipogems raised €12.5 million (~USD $13.2 million) in growth capital in 2022 to support the recent FDA-approved Investigational Device Exemption studies for a separate and specific indication in knee osteoarthritis (OA).
Lipogems’ minimally invasive procedure is performed one time in a sterile setting (outpatient or operating room) in about 40 minutes, and has shown in independent, investigator-initiated studies to improve the pain, function and quality of life of patients with knee OA.
Investors are providing Lipogems with the financial resources necessary to:
Pave the pathway for a knee OA indication and reimbursement in the US
Build infrastructure to support growth
Educate and raise awareness to consumers and patients about knee OA
Expand into other markets with common conditions that have limited therapeutic options and where MicroFat can provide life-changing relief
“In this highly regulated field, Lipogems is the proven leader in adipose tissue technologies and is currently being utilized in 250+ US orthopaedic centers and military installations, with 60,000 procedures performed to date worldwide. Of the 125+ independent peer-reviewed publications supporting Lipogems, over 35 are in Knee OA and this FDA study will prove the positive results that are commonly seen in this prevalent and disabling condition. This study and new funding validates our responsible regulatory and commercialization strategy and the trust our shareholder’s hold in Lipogems. Our roadmap is geared to provide common debilitating conditions have a simple and effective treatment option,” said Carl Llewellyn, CEO and President of Lipogems USA.
Lipogems raised €12.5 million (~USD $13.2 million) in growth capital in 2022 to support the recent FDA-approved Investigational Device Exemption studies for a separate and specific indication in knee osteoarthritis (OA).
Lipogems' minimally invasive procedure is performed one time in a sterile setting (outpatient or operating room) in...
Lipogems raised €12.5 million (~USD $13.2 million) in growth capital in 2022 to support the recent FDA-approved Investigational Device Exemption studies for a separate and specific indication in knee osteoarthritis (OA).
Lipogems’ minimally invasive procedure is performed one time in a sterile setting (outpatient or operating room) in about 40 minutes, and has shown in independent, investigator-initiated studies to improve the pain, function and quality of life of patients with knee OA.
Investors are providing Lipogems with the financial resources necessary to:
Pave the pathway for a knee OA indication and reimbursement in the US
Build infrastructure to support growth
Educate and raise awareness to consumers and patients about knee OA
Expand into other markets with common conditions that have limited therapeutic options and where MicroFat can provide life-changing relief
“In this highly regulated field, Lipogems is the proven leader in adipose tissue technologies and is currently being utilized in 250+ US orthopaedic centers and military installations, with 60,000 procedures performed to date worldwide. Of the 125+ independent peer-reviewed publications supporting Lipogems, over 35 are in Knee OA and this FDA study will prove the positive results that are commonly seen in this prevalent and disabling condition. This study and new funding validates our responsible regulatory and commercialization strategy and the trust our shareholder’s hold in Lipogems. Our roadmap is geared to provide common debilitating conditions have a simple and effective treatment option,” said Carl Llewellyn, CEO and President of Lipogems USA.
Copy to clipboard 
